ClinicalTrials.gg
RecruitingNCT06080659NODALUpdated Jan 5, 2026

Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity

An interventional study of fMRI and CONFMEM in Alzheimer Disease, Early Onset and Parkinson Disease, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 438 studies in Alzheimer Disease with a site in France — 81 open to participants now, 97 under way, 18 of them phase 3. Alzheimer Disease · France.

Planned enrollment
189th of 341
120 · median 152
Started
2023
with 19 others
No phase
168 of 438
30 open now
Primary completion
2026-11
later than 25 of 96 live
Registered
373rd of 438
by date

Among the 438 studies in Alzheimer Disease with a site in France, this one is the 189th largest by planned enrollment of the 341 interventional ones that give a count, is one of 20 that started in 2023, is one of 168 with no phase, reaches primary completion later than 25 of the 96 other live ones, and was the 373rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

81 of the 438 studies in Alzheimer Disease with a site in France are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 438 studies in Alzheimer Disease with a site in France, or all of them as a file.
02

Study summary

The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.

Read the detailed description

Alzheimer's (AD) and Parkinson's (PD) diseases are characterized by pre-clinical and asymptomatic phases, which can extend over decades, before progressing through different clinical stages where cognitive and/or motor symptoms appear. A major challenge for clinical neuroscience is the availability of reliable, non-invasive and inexpensive biomarkers to enable early diagnosis, be clinically relevant, and ideally contribute to prognosis and patient monitoring.

Current criteria, which are essentially clinical, have a relatively low diagnostic accuracy, which is unfortunately responsible for a delay in diagnosis, whereas it has been established that early diagnosis makes it possible to postpone the loss of autonomy, open up opportunities for clinical trials for patients, and, epidemiologically speaking, ultimately reduce the prevalence of major neurocognitive disorders.

Recent advances in neuroimaging techniques and connectome analysis have led to the identification of innovative biomarkers that reflect the disorganization of brain networks and are associated with clinical symptoms.

After participant inclusion, the experimental visit will take place over half a day, for patients with early-stage Alzheimer's or Parkinson's disease and for healthy control volunteers.

After clinical assessment, participants will undergo an MRI scan and then perform the CONFMEM experimental task.

The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

The cerebral connectome will be assessed for each patient, with the aim of determining whether patterns can lead to pathology-specific markers.

03

Conditions studied

  • Alzheimer Disease, Early Onset
  • Parkinson Disease

Keywords

  • connectome
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all participants:
  • French mother tongue
  • right-handed
  • with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate)
  • Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients)
  • Affiliated with a social security scheme
  • Having received oral and written information about the protocol and having signed a consent form to participate in this research.

DCS+ group:

- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014).

Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA":

- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011))

De novo" Parkinsonian patients, "MPdn":

- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015))

Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP":

- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012))

Exclusion criteria

Exclusion Criteria:

  • All participants (healthy volunteers and patients)
  • to MRI :
  • Abdominal circumference + upper limbs sticking to the body > 200 cm;
  • Implantable pacemaker or defibrillator;
  • Neurosurgical clips;
  • Cochlear implants ;
  • Neural or peripheral stimulator;
  • Intra-orbital or encephalic metallic foreign bodies;
  • Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago;
  • Claustrophobia.
  • Pregnant or breast-feeding women;
  • Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.

Patients only

  • Score >2 on the modified Hachinski scale (Hachinski et al., 2012)
  • Dementia according to McKhann criteria (McKhann et al., 2011)
  • Sensory deficit interfering with experimental tests

Healthy volunteers only

- Cognitive impairment ( score \< 26)

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    DCS+

    Patient with subjective cognitive decline, prodromal condition of Alzheimer's disease

    Diagnostic Test: fMRI · Diagnostic Test: CONFMEM

  • Experimental
    TCL-MA

    Patient with mild neurocognitive disorder linked to Alzheimer's disease

    Diagnostic Test: fMRI · Diagnostic Test: CONFMEM

  • Experimental
    MPdn

    early-stage or de novo Parkinson's disease patients with no cognitive deficits

    Diagnostic Test: fMRI · Diagnostic Test: CONFMEM

  • Experimental
    TCL-MP

    Patient with mild neurocognitive disorder linked to Parkinson's disease

    Diagnostic Test: fMRI · Diagnostic Test: CONFMEM

  • Active comparator
    Healthy volunteers

    Healthy volunteers

    Diagnostic Test: fMRI · Diagnostic Test: CONFMEM

Interventions

  • Diagnostic testfMRI

    functional MRI

  • Diagnostic testCONFMEM

    The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

06

What researchers measure

Primary outcomes

  1. Multimodal connectivity graph metrics across diseases

    Multi-layer graph combining the functional and structural connectivity will provide an ideal framework for identifying multimodal features. The first layer corresponds to the functional connectivity where links represent the similarity between the fMRI signal from different cerebral regions (i.e. the nodes), using the cross-correlation. The second layer represents the structural connectivity where the edges are the fiber density between the nodes. Topological metrics of graph: 1/ the nodal centrality which quantifies how important a node is within a network, 2/ the betweenness defined as the ratio of the number of the shortest paths comprising the node to the total number of shortest paths in the graph, measures the hub property of the node and 3/ local efficiency which quantify the ability of a network to transmit information at the global and local level, will be compared between patients at-risk for Alzheimer's Disease, patients with Parkinson's Disease and healthy controls.

    Time frame: 2 hours and 30 minutes

Secondary outcomes

  1. Multimodal connectivity graph metrics across stages of disease

    Multi-layer graph combining the functional and structural connectivity will provide an ideal framework for identifying multimodal features. The first layer corresponds to the functional connectivity where links represent the correlation between the fMRI signal. The second layer represents the structural connectivity where the edges are the fiber density between the nodes. Topological metrics of graph: 1/ the nodal centrality which quantifies how important a node is within a network, 2/ the betweenness defined as the ratio of the number of the shortest paths comprising the node to the total number and 3/ local efficiency which quantify the ability of a network to transmit information, will be compared between patients at-risk for Alzheimer's Disease at the Subjective Cognitive Decline stage and at the Mild Cognitive Impairment stage. Similarly, patients with Parkinson's Disease without cognitive impairment and with Parkinson's Disease with Mild Cognitive will be compared.

    Time frame: 2 hours and 30 minutes

  2. Correlation between multimodal connectivity graph metrics and cognitive scores

    Cognitive scores will include standard tasks (MOCA, Symbol Digit Modality Test - oral, Digit span, 16-items Free \& Cued Selective Reminding Test, 10/36 spatial recall test, Oral Letter-Number Sequencing test, D-KEFS Color-Word Interference Test, Benton Judgment of Line Orientation, CLOX clock-drawing test, Boston Naming Test, Animal fluency) and an experimental recognition memory task. As for the latter, the scores used will be the congruency effect during study (RT in milliseconds), global recognition accuracy, and the effect of congruency on subsequent memory (difference in recognition accuracy between congruent and incongruent trials at study).

    Time frame: Up to 6 months (maximum delay between the study visit and the collection of standard tasks).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 36 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Oct 12, 2023
StartActual
Nov 6, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06080659
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Nov 6, 2023
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 5, 2026

Study contacts

marie-laure gervais, Phd
Contact
marie-laure.gervais@chu-rennes.fr
299282555 ext. +33
Pierre-Yves JONIN, PhD
Contact
pierreyves.jonin@chu-rennes.fr
299284321 ext. +33
Pierre-Yves JONIN, PhD
principal investigator · Rennes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion